Sökning: "haematopoietic stem cell transplantation"
Visar resultat 1 - 5 av 24 avhandlingar innehållade orden haematopoietic stem cell transplantation.
1. Novel Insights into Haematopoietic Stem Cell Regulation and Function
Sammanfattning : The haematopoietic stem cell (HSC) is a somatic stem cell essential for life long haematopoiesis; HSCs have the capability to differentiate into all mature types of blood cells and can also undergo self-renewal to maintain their own numbers. They also have the potential to reconstitute a complete haematopoietic system following HSC transplantation, also known as bone marrow transplantation, which is used to treat many haematopoietic disorders. LÄS MER
2. Allogeneic stem cell transplantation : patients’ and sibling donors’ perspectives
Sammanfattning : Allogeneic haematopoietic stem cell transplantation (hereafter HSCT) is an established treatment which offers a potential cure for a variety of diseases, mainly haematological malignancies. However, the treatment is also associated with significant risks of acute complications and late side effects, including mortality. LÄS MER
3. Potential Hazards for Haematopoietic Stem Cell Donors
Sammanfattning : The aim of this thesis has been to increase our knowledge about the allogeneic stem cell donation procedure and the associated risks for stem cell donors. In a first study (paper I), we described the donation procedure and short-term side effects of 1957 donors included in the Nordic Register of Haematopoietic Stem Cell Donors. LÄS MER
4. Cytokine production in allogeneic haematopoietic stem-cell transplantation patients
Sammanfattning : Severe immunological complications may occur after haematopoietic stem-cell transplantation (HSCT). These include acute graft-versus-host disease (GVHD), veno-occlusive disease of the liver (VOD) and severe infections. LÄS MER
5. Immune reconstitution after allogeneic hematopoietic stem cell transplantation
Sammanfattning : After treatment with allogeneic hernatopoietic stem cell transplantation (HSCT) the patient suffers from a deficient immune system for at least 12 months or longer. During this period, the patient is susceptible to infections and if the state of immune deficiency is prolonged there is an increased risk of relapse of the underlying malignancy as well as development of secondary malignancies. LÄS MER